Analysts Offer Insights on Technology Companies: ON Semiconductor (ON), Tokyo Electron (OtherTOELF) and Nvidia (NVDA)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ON Semiconductor (ON)
In a report issued on July 10, Christopher Rolland from Susquehanna reiterated a Buy rating on ON Semiconductor, with a price target of $50.00. The company's shares closed last Monday at $59.07.
According to TipRanks.com, Rolland is a 5-star analyst with an average return of 17.7% and a 59.2% success rate. Rolland covers the Technology sector, focusing on stocks such as Credo Technology Group Holding Ltd, Infineon Technologies AG, and Advanced Micro Devices. ;'>
Currently, the analyst consensus on ON Semiconductor is a Moderate Buy with an average price target of $54.65, implying a -7.6% downside from current levels. In a report issued on July 3, CFRA also upgraded the stock to Buy with a $75.00 price target.
Tokyo Electron (TOELF)
In a report released today, David Dai CFA from Bernstein maintained a Buy rating on Tokyo Electron, with a price target of Yen33800.00. The company's shares closed last Monday at $173.73.
According to TipRanks.com, CFA is a 2-star analyst with an average return of 0.6% and a 56.3% success rate. CFA covers the Technology sector, focusing on stocks such as Infineon Technologies AG, Renesas Electronics, and SCREEN Holdings Co. ;'>
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tokyo Electron with a $221.61 average price target, a 30.0% upside from current levels. In a report issued on June 30, Goldman Sachs also maintained a Buy rating on the stock with a Yen33000.00 price target.
Nvidia (NVDA)
In a report released today, Stacy Rasgon from Bernstein maintained a Buy rating on Nvidia, with a price target of $185.00. The company's shares closed last Monday at $164.07.
According to TipRanks.com, Rasgon is a 5-star analyst with an average return of 24.3% and a 67.2% success rate. Rasgon covers the Technology sector, focusing on stocks such as Advanced Micro Devices, NXP Semiconductors, and Texas Instruments. ;'>
Currently, the analyst consensus on Nvidia is a Strong Buy with an average price target of $176.76, a 6.9% upside from current levels. In a report issued on July 10, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $185.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
RXST BREAKING NEWS: BFA Law is Investigating RxSight, Inc. for Securities Fraud; Contact the Firm about how to Potentially Recover Investment Losses
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: Why is RxSight being Investigated? RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company's main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens's shape and power to optimize vision based on the patient's individual needs and preferences. During the relevant period, the Company touted its strong LAL and LDD sales. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024. The Stock Declines as the Truth is Revealed On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a 'softening' of the market that purportedly occurred 'in the second half of 2024.' On this news, the price of RxSight stock declined roughly 38%, from $26.12 per share on April 2, 2025, to $16.21 per share on April 3, 2025. Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to 'the slower ramp in LAL utilization that was first noted in 2024.' On this news, the price of RxSight stock declined roughly 38%, from $12.79 per share on July 8, 2025, to $7.95 per share on July 9, 2025. Click here for more information: What Can You Do? If you invested in RxSight you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz ross@ 212-789-3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit
Globe and Mail
24 minutes ago
- Globe and Mail
PNC Financial Reports Strong Q2 2025 Results
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. PNC Financial ( (PNC)) has issued an announcement. On July 16, 2025, PNC Financial Services Group reported strong financial results for the second quarter of 2025, with a net income of $1.6 billion and a 4% revenue growth. The company experienced its strongest loan growth since the fourth quarter of 2022, maintained stable noninterest expenses, and announced a dividend increase, reflecting its continued financial strength. PNC's strategic priorities include expanding its client base and leveraging technology for superior client service, which contributed to record treasury management revenue and increased brokerage assets. The company also reported improved credit quality and maintained its stress capital buffer at the regulatory minimum. The most recent analyst rating on (PNC) stock is a Buy with a $212.00 price target. To see the full list of analyst forecasts on PNC Financial stock, see the PNC Stock Forecast page. Spark's Take on PNC Stock According to Spark, TipRanks' AI Analyst, PNC is a Outperform. PNC Financial's strong financial performance and strategic focus on capital return are the most significant factors driving the score. The technical analysis suggests caution due to overbought signals, while the valuation remains fair with an attractive dividend yield. The earnings call reinforces confidence in PNC's resilience despite potential market challenges. To see Spark's full report on PNC stock, click here. More about PNC Financial PNC Financial Services Group, Inc. operates in the financial services industry, offering a wide range of financial products and services on a national basis. The company focuses on corporate banking, business credit, treasury management, retail banking, and asset management, leveraging technology to enhance client service and ensure safety and soundness. Average Trading Volume: 2,267,611 Technical Sentiment Signal: Strong Buy Current Market Cap: $78.08B For detailed information about PNC stock, go to TipRanks' Stock Analysis page.
Globe and Mail
24 minutes ago
- Globe and Mail
Securities Fraud Investigation Into Encompass Health Corporation (EHC) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Encompass Health Corporation ('Encompass' or the 'Company') (NYSE: EHC) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ENCOMPASS HEALTH CORPORATION (EHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On July 15, 2025, The New York Times published an article alleging, among other things, that federal data and inspection reports show that for-profit hospitals run by Encompass perform below average on key safety measures. The article revealed 'Encompass owns many of the rehabs with worse rates of potentially preventable, unplanned readmissions to general hospitals' including 34 facilities which 'Medicare rated as having statistically significantly worse rates of potentially preventable readmissions.' The report further revealed a number of 'alarming mistakes' leading to fatalities of patients in their care. On this news, Encompass's stock price fell $12.39, or 10.4%, to close at $107.28 per share on July 15, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Encompass should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
